FDA Acceptance of Calcipotriene Supplement by Glenmark
The FDA's acceptance of Glenmark's supplement application for Calcipotriene is a significant regulatory milestone that could enhance their competitive positioning in the psoriasis market. This development necessitates close monitoring of Glenmark's progress and potential responses from competitors.
Asset
Glenmark
Indication
Dermatology / Psoriasis
Status
Approved
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The FDA's acceptance of Glenmark's supplement application for Calcipotriene is a significant regulatory milestone that could enhance their competitive positioning in the psoriasis market. This development necessitates close monitoring of Glenmark's progress and potential responses from competitors.
Why it matters
The FDA's acceptance of Glenmark's supplement application for Calcipotriene is a significant regulatory milestone that could enhance their competitive positioning in the psoriasis market. This development necessitates close monitoring of Glenmark's progress and potential responses from competitors.
What changed
Regulatory Approval
Analysis
The FDA has accepted the supplement application ANDA205772 for Calcipotriene submitted by Glenmark.
The FDA's acceptance of Glenmark's supplement application for Calcipotriene is a significant regulatory milestone that could enhance their competitive positioning in the psoriasis market. This development necessitates close monitoring of Glenmark's progress and potential responses from competitors.
Monitor the progress of the review process and any subsequent approvals or market entries related to Calcipotriene.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.